SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Barclays

Stock analysts at Barclays began coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note issued on Wednesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $13.00 price target on the stock. Barclays‘s price target would indicate a potential upside of 235.92% from the stock’s current price.

SABS has been the topic of a number of other reports. Citigroup began coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $11.00 price target on the stock. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of SAB Biotherapeutics in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Finally, Leerink Partners lifted their price target on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $12.00.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.87 on Wednesday. The stock has a market cap of $295.92 million, a PE ratio of -1.83 and a beta of 0.54. The stock has a 50-day moving average of $3.71 and a 200-day moving average of $3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. SAB Biotherapeutics has a one year low of $1.67 and a one year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). As a group, sell-side analysts expect that SAB Biotherapeutics will post -1.19 earnings per share for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in SABS. Vivo Capital LLC acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $22,954,000. Perceptive Advisors LLC lifted its stake in shares of SAB Biotherapeutics by 700.8% in the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after acquiring an additional 5,628,533 shares during the last quarter. RA Capital Management L.P. acquired a new stake in shares of SAB Biotherapeutics during the 3rd quarter valued at $8,847,000. Commodore Capital LP bought a new stake in SAB Biotherapeutics during the 3rd quarter worth $8,847,000. Finally, Woodline Partners LP bought a new stake in SAB Biotherapeutics during the 3rd quarter worth $5,730,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.